tetano
Editor, Senior Moderator
Balkan Med J
. 2023 Oct 20;40(6):435-444.
doi: 10.4274/balkanmedj.galenos.2023.2023-6-90. The Impact of CoronaVac Vaccination on 28-day Mortality Rate of Critically Ill Patients with COVID-19 in Türkiye
Fethi Gül[SUP] 1 [/SUP], Umut Sabri Kasapoğlu[SUP] 2 [/SUP], Mehmet Süleyman Sabaz[SUP] 3 [/SUP], Pınar Ay[SUP] 4 [/SUP], Burçin Doruk Oktay[SUP] 1 [/SUP], Gülbahar Çalışkan[SUP] 5 [/SUP], Nalan Demir[SUP] 6 [/SUP], İsmet Sayan[SUP] 7 [/SUP], Feyyaz Kabadayı[SUP] 7 [/SUP], Gülsüm Altuntaş[SUP] 8 [/SUP], Ayça Gümüş[SUP] 9 [/SUP], Hülya Kırca[SUP] 9 [/SUP], Deniz Şanlı[SUP] 10 [/SUP], Fatma Acil[SUP] 11 [/SUP], Andaç Dedeoğlu[SUP] 11 [/SUP], Sedef Gülçin Ural[SUP] 12 [/SUP], İrem Akın Şen[SUP] 12 [/SUP], Eda Macit Aydın[SUP] 13 [/SUP], Hakan Dayanır[SUP] 13 [/SUP], Birgül Yelken[SUP] 14 [/SUP], İlkay Ceylan[SUP] 15 [/SUP], Osman Özcan Aydın[SUP] 14 [/SUP], Güneş Eskidemir[SUP] 16 [/SUP], Ahmet Aytekin[SUP] 17 [/SUP], Melike Cengiz[SUP] 18 [/SUP], Ülkü Arslan[SUP] 18 [/SUP], Devrim Akdağ[SUP] 19 [/SUP], Gülçin Hilal Alay[SUP] 20 [/SUP], Esra Tekin[SUP] 21 [/SUP], Volkan Yarar[SUP] 22 [/SUP], Kemal Tolga Saracoğlu[SUP] 23 [/SUP], Funda Gök[SUP] 24 [/SUP], Volkan Alparslan[SUP] 25 [/SUP], Verda Tuna[SUP] 26 [/SUP], Murside Yıldız[SUP] 27 [/SUP], Nimet Şenoğlu[SUP] 28 [/SUP], Cenk Kıraklı[SUP] 29 [/SUP], Süleyman Yıldırım[SUP] 29 [/SUP], Kübra Saçar Kübüç[SUP] 30 [/SUP], Ayşen Erer[SUP] 31 [/SUP], Hamza Gültekin[SUP] 32 [/SUP], Kezban Özmen Süner[SUP] 33 [/SUP], Özge Kuzgun[SUP] 33 [/SUP], Çağatay Erman Öztürk[SUP] 34 [/SUP], Aydın Karahan[SUP] 35 [/SUP], Okan Deveci[SUP] 35 [/SUP], Mustafa Ay[SUP] 36 [/SUP], Dilara Tüfek Öztan[SUP] 36 [/SUP], Seda Banu Akıncı[SUP] 37 [/SUP], Melahat Yalçın Solak[SUP] 37 [/SUP], Süha Bozbay[SUP] 38 [/SUP], Serhat Özçiftçi[SUP] 38 [/SUP], Kamil Gönderen[SUP] 39 [/SUP], Ahmet Oğuzhan Küçük[SUP] 40 [/SUP], Berna Uyan[SUP] 41 [/SUP], Gülseren Elay[SUP] 42 [/SUP], Nazlıhan Boyacı[SUP] 43 [/SUP], Mustafa Timurkaan[SUP] 8 [/SUP], Ebru Karakoç[SUP] 44 [/SUP], Lerzan Doğan[SUP] 45 [/SUP], Erdem Yalçınkaya[SUP] 46 [/SUP], Leyla Kazancıoğlu[SUP] 47 [/SUP], Gül Erdal Dönmez[SUP] 48 [/SUP], Barış Yılmaz[SUP] 48 [/SUP], Dursun Fırat Ergül[SUP] 49 [/SUP], Maruf Boran[SUP] 49 [/SUP], Hüseyin Özkarakaş[SUP] 50 [/SUP], Buğra Karakaş[SUP] 51 [/SUP], Perihan Ergin Özcan[SUP] 52 [/SUP], İlkay Anaklı[SUP] 52 [/SUP], Mustafa Kemal Bayar[SUP] 53 [/SUP], Didem Yüksel Yüksel[SUP] 53 [/SUP], Şükriye Akdağ[SUP] 54 [/SUP], Özcan Pişkin[SUP] 55 [/SUP], Sibel Temur[SUP] 56 [/SUP], Selin Eyüpoğlu[SUP] 57 [/SUP], Elvan Tekir Yılmaz[SUP] 58 [/SUP], Gizem Zaim Avcı[SUP] 59 [/SUP], Raziye Turan[SUP] 59 [/SUP], Fatma Alkan Bayburt[SUP] 59 [/SUP], Helin Şahintürk[SUP] 60 [/SUP], Bülent Güçyetmez[SUP] 61 [/SUP], Mustafa Muhlis Alparslan[SUP] 62 [/SUP], Metin Yarıcı[SUP] 63 [/SUP], Fatma Yıldırım[SUP] 64 [/SUP], Abdulkadir Yektaş[SUP] 65 [/SUP], Güçlü Yaman[SUP] 66 [/SUP], Oktay Demirkıran[SUP] 67 [/SUP], İsmail Cinel[SUP] 1 [/SUP]
Affiliations
Background: Vaccines against coronavirus disease-19 (COVID-19) have been effective in preventing symptomatic diseases, hospitalizations, and intensive care unit (ICU) admissions. However, data regarding the effectiveness of COVID-19 vaccines in reducing mortality among critically ill patients with COVID-19 remains unclear.
Aims: To determine the vaccination status and investigate the impact of the COVID-19 vaccine on the 28-day mortality in critically ill patients with COVID-19.
Study design: Multicenter prospective observational clinical study.
Methods: This study was conducted in 60 hospitals with ICUs managing critically ill patients with COVID-19. Patients aged ≥ 18 years with confirmed COVID-19 who were admitted to the ICU were included. The present study had two phases. The first phase was designed as a one-day point prevalence study, and demographic and clinical findings were evaluated. In the second phase, the 28-day mortality was evaluated.
Results: As of August 11, 2021, 921 patients were enrolled in the study. The mean age of the patients was 65.42 ± 16.74 years, and 48.6% (n = 448) were female. Among the critically ill patients with COVID-19, 52.6% (n = 484) were unvaccinated, 7.7% (n = 71) were incompletely vaccinated, and 39.8% (n = 366) were fully vaccinated. A subgroup analysis of 817 patients who were unvaccinated (n = 484) or who had received two doses of the CoronaVac vaccine (n = 333) was performed. The 28-day mortality rate was 56.8% (n = 275) and 57.4% (n = 191) in the unvaccinated and two-dose CoronaVac groups, respectively. The 28-day mortality was associated with age, hypertension, the number of comorbidities, type of respiratory support, and APACHE II and sequential organ failure assessment scores (p < 0.05). The odds ratio for the 28-day mortality among those who had received two doses of CoronaVac was 0.591 (95% confidence interval: 0.413-0.848) (p = 0.004).
Conclusion: Vaccination with at least two doses of CoronaVac within six months significantly decreased mortality in vaccinated patients than in unvaccinated patients.
. 2023 Oct 20;40(6):435-444.
doi: 10.4274/balkanmedj.galenos.2023.2023-6-90. The Impact of CoronaVac Vaccination on 28-day Mortality Rate of Critically Ill Patients with COVID-19 in Türkiye
Fethi Gül[SUP] 1 [/SUP], Umut Sabri Kasapoğlu[SUP] 2 [/SUP], Mehmet Süleyman Sabaz[SUP] 3 [/SUP], Pınar Ay[SUP] 4 [/SUP], Burçin Doruk Oktay[SUP] 1 [/SUP], Gülbahar Çalışkan[SUP] 5 [/SUP], Nalan Demir[SUP] 6 [/SUP], İsmet Sayan[SUP] 7 [/SUP], Feyyaz Kabadayı[SUP] 7 [/SUP], Gülsüm Altuntaş[SUP] 8 [/SUP], Ayça Gümüş[SUP] 9 [/SUP], Hülya Kırca[SUP] 9 [/SUP], Deniz Şanlı[SUP] 10 [/SUP], Fatma Acil[SUP] 11 [/SUP], Andaç Dedeoğlu[SUP] 11 [/SUP], Sedef Gülçin Ural[SUP] 12 [/SUP], İrem Akın Şen[SUP] 12 [/SUP], Eda Macit Aydın[SUP] 13 [/SUP], Hakan Dayanır[SUP] 13 [/SUP], Birgül Yelken[SUP] 14 [/SUP], İlkay Ceylan[SUP] 15 [/SUP], Osman Özcan Aydın[SUP] 14 [/SUP], Güneş Eskidemir[SUP] 16 [/SUP], Ahmet Aytekin[SUP] 17 [/SUP], Melike Cengiz[SUP] 18 [/SUP], Ülkü Arslan[SUP] 18 [/SUP], Devrim Akdağ[SUP] 19 [/SUP], Gülçin Hilal Alay[SUP] 20 [/SUP], Esra Tekin[SUP] 21 [/SUP], Volkan Yarar[SUP] 22 [/SUP], Kemal Tolga Saracoğlu[SUP] 23 [/SUP], Funda Gök[SUP] 24 [/SUP], Volkan Alparslan[SUP] 25 [/SUP], Verda Tuna[SUP] 26 [/SUP], Murside Yıldız[SUP] 27 [/SUP], Nimet Şenoğlu[SUP] 28 [/SUP], Cenk Kıraklı[SUP] 29 [/SUP], Süleyman Yıldırım[SUP] 29 [/SUP], Kübra Saçar Kübüç[SUP] 30 [/SUP], Ayşen Erer[SUP] 31 [/SUP], Hamza Gültekin[SUP] 32 [/SUP], Kezban Özmen Süner[SUP] 33 [/SUP], Özge Kuzgun[SUP] 33 [/SUP], Çağatay Erman Öztürk[SUP] 34 [/SUP], Aydın Karahan[SUP] 35 [/SUP], Okan Deveci[SUP] 35 [/SUP], Mustafa Ay[SUP] 36 [/SUP], Dilara Tüfek Öztan[SUP] 36 [/SUP], Seda Banu Akıncı[SUP] 37 [/SUP], Melahat Yalçın Solak[SUP] 37 [/SUP], Süha Bozbay[SUP] 38 [/SUP], Serhat Özçiftçi[SUP] 38 [/SUP], Kamil Gönderen[SUP] 39 [/SUP], Ahmet Oğuzhan Küçük[SUP] 40 [/SUP], Berna Uyan[SUP] 41 [/SUP], Gülseren Elay[SUP] 42 [/SUP], Nazlıhan Boyacı[SUP] 43 [/SUP], Mustafa Timurkaan[SUP] 8 [/SUP], Ebru Karakoç[SUP] 44 [/SUP], Lerzan Doğan[SUP] 45 [/SUP], Erdem Yalçınkaya[SUP] 46 [/SUP], Leyla Kazancıoğlu[SUP] 47 [/SUP], Gül Erdal Dönmez[SUP] 48 [/SUP], Barış Yılmaz[SUP] 48 [/SUP], Dursun Fırat Ergül[SUP] 49 [/SUP], Maruf Boran[SUP] 49 [/SUP], Hüseyin Özkarakaş[SUP] 50 [/SUP], Buğra Karakaş[SUP] 51 [/SUP], Perihan Ergin Özcan[SUP] 52 [/SUP], İlkay Anaklı[SUP] 52 [/SUP], Mustafa Kemal Bayar[SUP] 53 [/SUP], Didem Yüksel Yüksel[SUP] 53 [/SUP], Şükriye Akdağ[SUP] 54 [/SUP], Özcan Pişkin[SUP] 55 [/SUP], Sibel Temur[SUP] 56 [/SUP], Selin Eyüpoğlu[SUP] 57 [/SUP], Elvan Tekir Yılmaz[SUP] 58 [/SUP], Gizem Zaim Avcı[SUP] 59 [/SUP], Raziye Turan[SUP] 59 [/SUP], Fatma Alkan Bayburt[SUP] 59 [/SUP], Helin Şahintürk[SUP] 60 [/SUP], Bülent Güçyetmez[SUP] 61 [/SUP], Mustafa Muhlis Alparslan[SUP] 62 [/SUP], Metin Yarıcı[SUP] 63 [/SUP], Fatma Yıldırım[SUP] 64 [/SUP], Abdulkadir Yektaş[SUP] 65 [/SUP], Güçlü Yaman[SUP] 66 [/SUP], Oktay Demirkıran[SUP] 67 [/SUP], İsmail Cinel[SUP] 1 [/SUP]
Affiliations
- PMID: 37867428
- DOI: 10.4274/balkanmedj.galenos.2023.2023-6-90
Background: Vaccines against coronavirus disease-19 (COVID-19) have been effective in preventing symptomatic diseases, hospitalizations, and intensive care unit (ICU) admissions. However, data regarding the effectiveness of COVID-19 vaccines in reducing mortality among critically ill patients with COVID-19 remains unclear.
Aims: To determine the vaccination status and investigate the impact of the COVID-19 vaccine on the 28-day mortality in critically ill patients with COVID-19.
Study design: Multicenter prospective observational clinical study.
Methods: This study was conducted in 60 hospitals with ICUs managing critically ill patients with COVID-19. Patients aged ≥ 18 years with confirmed COVID-19 who were admitted to the ICU were included. The present study had two phases. The first phase was designed as a one-day point prevalence study, and demographic and clinical findings were evaluated. In the second phase, the 28-day mortality was evaluated.
Results: As of August 11, 2021, 921 patients were enrolled in the study. The mean age of the patients was 65.42 ± 16.74 years, and 48.6% (n = 448) were female. Among the critically ill patients with COVID-19, 52.6% (n = 484) were unvaccinated, 7.7% (n = 71) were incompletely vaccinated, and 39.8% (n = 366) were fully vaccinated. A subgroup analysis of 817 patients who were unvaccinated (n = 484) or who had received two doses of the CoronaVac vaccine (n = 333) was performed. The 28-day mortality rate was 56.8% (n = 275) and 57.4% (n = 191) in the unvaccinated and two-dose CoronaVac groups, respectively. The 28-day mortality was associated with age, hypertension, the number of comorbidities, type of respiratory support, and APACHE II and sequential organ failure assessment scores (p < 0.05). The odds ratio for the 28-day mortality among those who had received two doses of CoronaVac was 0.591 (95% confidence interval: 0.413-0.848) (p = 0.004).
Conclusion: Vaccination with at least two doses of CoronaVac within six months significantly decreased mortality in vaccinated patients than in unvaccinated patients.